COMPASS Pathways Clinical Trial Network
Location: Multiple US Sites,
Hours: Trial enrollment by application
About COMPASS Pathways Clinical Trial Network
COMPASS Pathways is a pharmaceutical company running Phase 3 trials of COMP360 (synthetic psilocybin) for treatment-resistant depression across multiple US sites. Their Phase 3 interim data showed significant effect versus placebo in TRD. NDA submission expected late 2026 with FDA approval possible 2027-2028. If approved, COMP360 would be the first FDA-approved psilocybin product.
Location & Legal Context
COMPASS Pathways Clinical Trial Network operates in Multiple US Sites. Before visiting or purchasing, review the psilocybin laws in Multiple US Sites to understand the current legal landscape.
Community Reviews
Community reviews coming in Phase 2. Have you worked with COMPASS Pathways Clinical Trial Network? Share your experience in the forum.